# METFORMIN FOR ATRIAL FIBRILLATION

Study · id `cardio:ct-nct05878535` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05878535](<https://clinicaltrials.gov/study/NCT05878535>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05878535

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 770 participants.

## Technical summary

Registry record NCT05878535. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (anticipated); primary completion 2025-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 770 participants (planned count; ClinicalTrials.gov record NCT05878535, source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)
- Planned start: 2024-06-01 (anticipated) (ClinicalTrials.gov record NCT05878535, source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)
- Primary completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT05878535, source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)
- Completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT05878535, source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05878535, source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05878535-2024-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: METFORMIN FOR ATRIAL FIBRILLATION
- Acronym: MAFT
- Condition: Atrial Fibrillation
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: Arab Contractors Medical Centre
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 187991176ebb9552666433e241149cc82837c582bc2f2dae20232182f025d7f0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
